United Therapeutics Corporation
UTHR
$534.91
-$1.22-0.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.18B | 3.13B | 3.08B | 2.99B | 2.88B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.18B | 3.13B | 3.08B | 2.99B | 2.88B |
| Cost of Revenue | 384.40M | 356.90M | 339.10M | 329.30M | 309.70M |
| Gross Profit | 2.80B | 2.77B | 2.74B | 2.66B | 2.57B |
| SG&A Expenses | 756.20M | 728.70M | 701.00M | 666.10M | 640.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.69B | 1.63B | 1.56B | 1.52B | 1.43B |
| Operating Income | 1.49B | 1.50B | 1.52B | 1.47B | 1.45B |
| Income Before Tax | 1.71B | 1.67B | 1.62B | 1.56B | 1.54B |
| Income Tax Expenses | 379.20M | 394.70M | 374.90M | 353.20M | 343.90M |
| Earnings from Continuing Operations | 1.33K | 1.27K | 1.24K | 1.21K | 1.20K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.33B | 1.27B | 1.24B | 1.21B | 1.20B |
| EBIT | 1.49B | 1.50B | 1.52B | 1.47B | 1.45B |
| EBITDA | 1.58B | 1.58B | 1.60B | 1.55B | 1.52B |
| EPS Basic | 30.18 | 28.51 | 27.71 | 27.11 | 26.46 |
| Normalized Basic EPS | 23.61 | 23.49 | 23.63 | 22.91 | 22.17 |
| EPS Diluted | 27.90 | 26.38 | 25.61 | 25.05 | 24.59 |
| Normalized Diluted EPS | 21.84 | 21.74 | 21.84 | 21.17 | 20.60 |
| Average Basic Shares Outstanding | 177.10M | 178.50M | 179.30M | 178.60M | 180.70M |
| Average Diluted Shares Outstanding | 191.50M | 192.90M | 194.00M | 193.20M | 194.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |